Montreal, Quebec — September 2, 2025 — Leads & Copy — Defence Therapeutics Inc. has appointed Amie Phinney, PhD, MBA, as its Strategy & Business Advisor, effective immediately. Dr. Phinney will collaborate with senior leadership to refine the biotechnology company’s strategies, aligning them with new directions from recent scientific advances.
Dr. Phinney brings over 20 years of experience in life sciences commercialization, including roles at Abbott and AbbVie Pharmaceutical companies, Lakeside Discovery, and adMare BioInnovations. She also co-founded Block Biosciences Inc. and Discovery-2-Innovation Life Sciences Consulting.
According to Sébastien Plouffe, founder and CEO of Defence Therapeutics, Dr. Phinney’s scientific and strategic leadership will help the company capitalize on its momentum and position it for sustainable growth. Dr. Phinney expressed excitement to join Defence Therapeutics, citing the company’s groundbreaking science in antibody-delivered therapeutics.
Dr. Phinney holds a PhD in Biomedical Research from the University of Basel, Switzerland, and an MBA from Lake Forest Graduate School of Management in Chicago, USA.
Defence Therapeutics is a clinical-stage biotechnology company developing ADC products using its ACCUM® technology.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
Source: Defence Therapeutics Inc.
